Business Wire

UL Solutions Expands European HVAC Testing to Address Surging Heat Pump Market and New Regulations

28.5.2025 14:00:00 CEST | Business Wire | Press release

Share

The new laboratory in Italy supports heat pump manufacturers with advanced testing facilities, streamlined regulatory compliance services and sustainable heat pump performance evaluations for the European market.

UL Solutions, a global leader in applied safety science, today announced a significant expansion of its heating, ventilation and air conditioning (HVAC) testing facility in Carugate, Italy, addressing rapidly growing European demand for comprehensive heat pump performance and safety testing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250523113676/en/

Guests celebrate the opening of the expanded UL Solutions HVAC Laboratory on May 14, 2025, in Carugate, Italy. Pictured above left to right: Luca Maggioni​, mayor of Carugate; Mirko Bautz, regional vice president, Europe Central-East & South, UL Solutions; Alberto Uggetti, executive vice president and chief commercial officer​, UL Solutions; Alessio Dellanoce​, vice president and general manager, Appliances, HVAC and Lighting, UL Solutions;​ and Davide Atzeni, director and regional general manager, EMEA, Appliances, HVAC and Lighting, UL Solutions​.

This rising demand in turn is being driven by the widespread adoption of environmentally friendly refrigerants and evolving regulatory requirements. The expanded Carugate laboratory offers HVAC services that provide performance testing alongside the company’s established safety expertise, specifically catering to European manufacturers of heat pumps for both residential and commercial buildings. These services aim to help manufacturers adopt alternative refrigerants effectively and enhance confidence that they meet new standards while developing more efficient products.

Heat pumps efficiently heat and cool by moving existing heat. In winter, they draw heat from outside to warm a building, and in summer, they expel indoor heat to cool it, making this electricity-powered refrigerant cycle more energy-efficient than traditional systems.

Key new capabilities in the Carugate laboratory include energy-efficiency, safety and eco-design requirement testing for the environmental performance of air-to-water and water-to-water heat pumps. These tests focus on energy consumption in “standby” and “off” modes; how efficiently a heat pump moves heat energy; and sound power level, which measures operational noise. In addition, the laboratory offers wireless and electromagnetic compatibility analysis of heat pump operation when near electronic devices or electromagnetic emissions.

By complementing these services with UL Marketing Claim Verification and custom research and development programs, UL Solutions acts as a comprehensive service provider for heat pump manufacturers, helping them reduce testing lead times, comply with mandatory regulations and accelerate global market access.

“These enhanced capabilities in Europe reinforce our dedication to offering comprehensive, unified services for the HVAC sector,” said Alessio Dellanoce, vice president and general manager of the Appliances, HVAC and Lighting group at UL Solutions. “Having performance and safety testing conducted at one central laboratory in Europe simplifies the testing process for our customers and helps enable them to get their products to targeted markets faster, all while demonstrating that their products meet safety and efficiency requirements.”

The European air conditioning and commercial refrigeration sectors are navigating a transition shaped by climate change policies, including the need for HVAC testing. For example, the European Union’s “Fit for 55” plan, which aims for a 55% reduction in greenhouse gas emissions by 2030, requires assessment of heat pumps for energy performance. Concurrently, the HVAC industry is increasingly using alternative refrigerants such as R32 and R454B, as well as natural refrigerants such as R290, necessitating tests to address the unique properties of these refrigerants, particularly their flammability, to demonstrate their safety, performance and regulatory compliance.

As the HVAC industry evolves with new regulations and consumer demand for sustainable technologies, manufacturers must demonstrate progress toward sustainability without compromising safety or performance. In Europe, UL Solutions supports compliance with EU regulations like Ecodesign and the Ecodesign for Sustainable Products Regulation (ESPR), and is also a certification body for KEYMARK, the European certification mark showing the conformity of products with European standards.

Learn more about UL Solutions’ services for heat pumps.

About UL Solutions

A global leader in applied safety science, UL Solutions (NYSE: ULS) transforms safety, security and sustainability challenges into opportunities for customers in more than 110 countries. UL Solutions delivers testing, inspection and certification services, together with software products and advisory offerings, that support our customers’ product innovation and business growth. The UL Mark serves as a recognized symbol of trust in our customers’ products and reflects an unwavering commitment to advancing our safety mission. We help our customers innovate, launch new products and services, navigate global markets and complex supply chains, and grow sustainably and responsibly into the future. Our science is your advantage.

Source Code: ULS-IR

View source version on businesswire.com: https://www.businesswire.com/news/home/20250523113676/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye